ArticleJournal of the Endocrine Society2026
Real-world effectiveness of liraglutide in children with type 2 diabetes.
Article in Journal of the Endocrine Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Since liraglutide's approval for the treatment of type 2 diabetes (T2D) in children, no real-world studies have examined its clinical outcomes in adolescents. Objective: Compare hemoglobin A1c (HbA1c) changes in adolescents with T2D taking liraglutide in a clinical setting. Design: Retrospective cohort study from 2020 to 2023. Participants: Patients with T2D ages <18 years who were prescribed liraglutide. Patients were divided into 2 groups: treated (those with evidence of taking liraglutide for ≥26 weeks) and control (those prescribed but who did not take liraglutide). Main outcomes: Changes in HbA1c after 26 weeks of treatment were calculated. Secondary outcomes included HbA1c changes after 52 weeks, and body mass index (BMI) Results: There was a strong trend toward a decrease in HbA1c after 26 weeks of liraglutide treatment compared with control (-0.40 [-1.90, 0.20] vs +0.15 [-1.30, 0.88], Conclusion: Liraglutide shows potential benefits for lowering HbA1c and cholesterol in children with T2D in a clinical setting. Additional work is needed to understand how to optimize HbA1c improvements with liraglutide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.